OBJECTIVE:Patients with Alzheimer's disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA. METHODS: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks tCPAP in patients with AD and OSA. Polysomnography data from screening after one night and after 3 weeks of treatment were analyzed. Records were scored for percent of each sleep stage, total sleep time (TST), sleep efficiency (SE), sleep period (SP), time in bed (TIB), sleep onset (SO), wake time after sleep onset (WASO), and arousals. A randomized design comparing one night of pCPAP to tCPAP and a paired analysis combining 3 weeks of tCPAP were performed. RESULTS:Fifty-two participants (mean age=77.8 years, SD=7.3) with AD and OSA were included. After one treatment night, the tCPAP group had significantly less % Stage 1 (p=0.04) and more % Stage 2 sleep (p=0.02) when compared to the pCPAP group. In the paired analysis, 3 weeks of tCPAP resulted in significant decreases in WASO (p=0.005), % Stage 1 (p=0.001), arousals (p=0.005), and an increase in % Stage 3 (p=0.006). CONCLUSION: In mild to moderate AD patients with OSA, the use of tCPAP resulted in deeper sleep after just one night, with improvements maintained for 3 weeks.
RCT Entities:
OBJECTIVE:Patients with Alzheimer's disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in ADpatients with OSA. METHODS: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks tCPAP in patients with AD and OSA. Polysomnography data from screening after one night and after 3 weeks of treatment were analyzed. Records were scored for percent of each sleep stage, total sleep time (TST), sleep efficiency (SE), sleep period (SP), time in bed (TIB), sleep onset (SO), wake time after sleep onset (WASO), and arousals. A randomized design comparing one night of pCPAP to tCPAP and a paired analysis combining 3 weeks of tCPAP were performed. RESULTS: Fifty-two participants (mean age=77.8 years, SD=7.3) with AD and OSA were included. After one treatment night, the tCPAP group had significantly less % Stage 1 (p=0.04) and more % Stage 2 sleep (p=0.02) when compared to the pCPAP group. In the paired analysis, 3 weeks of tCPAP resulted in significant decreases in WASO (p=0.005), % Stage 1 (p=0.001), arousals (p=0.005), and an increase in % Stage 3 (p=0.006). CONCLUSION: In mild to moderate ADpatients with OSA, the use of tCPAP resulted in deeper sleep after just one night, with improvements maintained for 3 weeks.
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: C F Reynolds; D J Kupfer; L S Taska; C C Hoch; D E Sewitch; K Restifo; D G Spiker; B Zimmer; R S Marin; J Nelson Journal: J Clin Psychiatry Date: 1985-07 Impact factor: 4.384
Authors: Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira Journal: Metabolism Date: 2018-02-01 Impact factor: 8.694
Authors: Nadia Gosselin; Andrée-Ann Baril; Ricardo S Osorio; Marta Kaminska; Julie Carrier Journal: Am J Respir Crit Care Med Date: 2019-01-15 Impact factor: 21.405
Authors: B Guarnieri; M Musicco; P Caffarra; F Adorni; I Appollonio; D Arnaldi; A Bartoli; E Bonanni; U Bonuccelli; C Caltagirone; G Cerroni; L Concari; F I I Cosentino; S Fermi; R Ferri; G Gelosa; G Lombardi; S Mearelli; F Nobili; S Passero; R Perri; R Rocchi; P Sucapane; G Tognoni; S Zabberoni; S Sorbi Journal: Neurol Sci Date: 2014-07-19 Impact factor: 3.307